Expanded Treatment Opportunities for Patients with the Import of Sunlenca Injection and Sunlenca Tablet

The Ministry of Food and Drug Safety announced on April 8 that it has approved the import of two rare medicines for the treatment of human immunodeficiency virus (HIV-1) infection: Sunlenca Injection and Sunlenca Tablet (lenacapavir).


MFDS Approves Rare Medicines for HIV Infection Treatment View original image

HIV (human immunodeficiency virus) targets CD4+ T cells, a type of white blood cell, weakening the immune system. If left untreated, infection leads to acquired immunodeficiency syndrome (AIDS).


This drug is a selective inhibitor that targets the capsid protein of HIV-1. It suppresses HIV-1 replication by blocking entry into the cell nucleus, inhibiting viral assembly and release, and inducing the formation of abnormal capsids.


The Ministry stated that the medicine is indicated for adult patients with multidrug-resistant HIV-1 infection for whom previous antiretroviral therapies have failed and there are no other effective treatment options. It is expected to provide a new therapeutic opportunity for unmet medical needs where existing treatments are insufficient.



The Ministry of Food and Drug Safety designated this drug as number 46 under the "Global Innovative Products Fast-Track Review System (GIFT)" and proceeded with an accelerated review to ensure its prompt introduction into clinical practice.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing